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Abstract 
How cells respond to a myriad of stimuli with finite signaling machinery is central to 
immunology. In naive T cells, the inherent effect of ligand strength on activation pathways 
and endpoints remains controversial, confounded by environmental fluctuations and 
intercellular variability within populations. Here, we study how ligand potency affects CD8+ 
T cell activation in vitro using genome-wide RNA, multi-dimensional protein and functional 
measurements in single cells. Our data reveal that strong ligands drive more efficient and 
uniform activation than weak ligands, but all activated cells are fully cytolytic. Importantly, 
activation follows the same transcriptional pathways, regardless of ligand potency. Thus, 
stimulation strength does not intrinsically dictate T cell activation route or phenotype; 
instead it controls how rapidly and simultaneously cells initiate activation, allowing limited 
machinery to elicit wide-ranging responses. 
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Cytotoxic T lymphocytes (CTLs) are critical for immune defense against tumors and viral 
pathogens. These programmed killer cells develop from naive CD8+ T cells over a multi-day 
activation process that depends on the activating stimulus as well as the surrounding 
immunological environment. T cell activation begins when the T cell receptor (TCR) on a naive 
CD8+ T cell recognizes peptide-class I major histocompatibility complexes (pMHC) on an antigen 
presenting cell (APC)1,2. If the TCR-pMHC interaction is strong enough to overcome negative 
feedback loops that control basal T cell signaling, additional signaling components are recruited 
to the plasma membrane. This initiates multiple coordinated enzymatic cascades that regulate 
integrin affinity, cytoskeletal rearrangements, metabolic changes and transcription factor activity, 
which are essential for T cell proliferation and effector differentiation.  
 
Altering the affinity of the TCR-pMHC interaction can dramatically affect immunological 
outcomes in both thymic selection and T cell activation in the periphery3,4. In thymocytes, TCR-
pMHC affinity determines whether cells undergo positive or negative selection5-7. In the periphery, 
different studies have found T cell responses to be graded or thresholded with respect to ligand 
affinity, with stronger ligands generally inducing a larger T cell response8-13. In vitro studies have 
observed that reducing ligand affinity can decrease molecular readouts of naive CD8+ T cell 
activation including calcium fluxes, kinase and transcription factor activity, surface receptor and 
cytokine expression, and proliferation5,11,13-23. Similarly, changing ligand concentration or 
costimulatory signals can affect T cell activation11,16,21,24-28. However, T cell activation assays 
differ between studies, with some reported as analog and others digital with respect to ligand 
affinity3,4,17,18,21,23,27,29,30. Additionally, reports conflict over whether ligand potency controls 
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response magnitude13,15,16,20, speed19, frequency17,18, or a combination thereof21,22,30. A substantial 
challenge in investigating early T cell activation is that populations of identically stimulated T 
cells exhibit extensive heterogeneity. Previous studies were limited in the number of markers that 
could be examined in individual cells or required pooled populations for genome-wide 
measurements. Thus, it has been difficult to identify the intrinsic mechanism by which ligand 
potency affects the integrated organization of gene expression changes within an individual cell. 
Single-cell technologies now allow individual cells to be interrogated at the molecular level in an 
unbiased, genome-wide manner, enabling us to address this question.  
 
Here we employ five single-cell methods to measure the genome-wide transcriptomes and targeted 
proteomic and functional profiles of naive CD8+ T cells activated in a controlled in vitro 
environment with peptide ligands of various potencies. We find that reducing ligand potency 
decreases the rate with which single T cells initiate transcriptional activation, driving increased 
heterogeneity in the pool of cells. However, we observe that all cells that activate, regardless of 
the potency of their primary stimulus, can achieve the same spectrum of effector protein profiles, 
are capable of cytolytic granule release, and reach this activated state using the same transcriptional 
pathway. Thus, we show that stimulation strength dictates how rapidly and uniformly cells 
respond. 
 
Results: 
 
Distinct transcriptional phases of early T cell activation 
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We first sought to characterize transcriptomic changes during the initial six hours of naive CD8+ 
T cell activation by single-cell RNA-sequencing (scRNA-seq). We used the OT-I transgenic TCR 
model to facilitate strict control over the timing of antigen encounter and the strength of the 
activating stimulus. Cells were isolated from OT-I TCR transgenic Rag1-deficient mice, in which 
all peripheral CD8+ T cells recognize the ovalbumin peptide SIINFEKL presented by the MHC 
class I molecule H-2Kb. Ex vivo CD8+ OT-I T cells were stimulated with pure peptide for self-
presentation to avoid contamination by antigen-presenting-cell RNA. By staining cells for surface 
protein expression before sorting into lysis buffer for scRNA-seq, we simultaneously measured 
expression of four surface proteins and quantified genome-wide mRNA in the same cells. We 
assayed one protein that is downregulated with activation, CD62L (L-selectin, encoded by Sell), 
and three proteins upregulated with activation, CD69, CD25 (encoded by Il2ra) and CD44.  
 
We first profiled a time course of strong stimulation by sequencing the transcriptomes of individual 
OT-I CD8+ T cells after 0, 1, 3 and 6 hours of activation with 1 µM of the high potency OT-I TCR 
cognate peptide SIINFEKL (N4) in the presence of IL-2 (Supplementary Fig. 1a and Methods). 
87% of cells passed quality control filtering, resulting in 44-64 cells per condition. Protein profiles 
revealed a rapid drop in CD62L expression, followed by sequential increases in CD69, CD25 and 
CD44 expression (Fig. 1a). Surface protein measurements and principal components analysis 
applied to the mRNA data confirmed that, despite a uniform activation stimulus, these cells were 
heterogeneous during the first 6 hours of activation (Fig. 1a,b). Because of this diversity, simply 
grouping the cells by sampling time cannot achieve the fine resolution required to understand 
coordination of gene expression. Instead, we took advantage of the heterogeneity within each 
stimulation condition to order all cells by their progressively changing transcriptional profiles, 
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referring to the progress in ‘pseudotime’ instead of real time. We used a diffusion pseudotime 
method31, a computational approach which finds the most direct path through the observed cell 
states based upon each cell’s gene expression profile. Fitting a diffusion pseudotime trajectory to 
the single-cell transcriptomic data, we created a fine-grained map of activation (Fig. 1c, 
Supplementary Fig. 1b).  
 
The distribution along pseudotime of all cells from the various time points revealed three clusters 
of resting, early activated and late activated cells (Fig. 1d, Supplementary Fig. 1c,d). We performed 
a differential expression analysis to compare each activated cluster to the resting cells. Cells in the 
early stages of activation primarily increased expression of genes involved in immune and 
regulatory processes, whereas cells in the later stages of activation showed strong upregulation of 
genes involved in metabolic and biosynthetic functions (Supplementary Table 1), which are critical 
for T cell effector differentiation32,33. We then examined genes differentially expressed in the early 
activation cluster compared to both the resting and late activation clusters to identify transient early 
expression changes. Filtering for differentially expressed genes uniquely upregulated in early 
activation revealed an enrichment for genes that encode transcriptional regulators (enrichment p 
value 1.8 x 10-9, Fig. 1e, Supplementary Fig. 1e). In particular, the early response NR4A family 
orphan nuclear receptors, including Nr4a1 (Nur77) whose expression has been found to reflect 
TCR signaling activity27,34-36, were most highly expressed 1 hour after activation (Fig. 1f). 
Additionally, early growth response factors (Egr1 and Egr2) and the AP-1 transcription factor 
subunit Fosb followed similar expression patterns. Thus, we identified two distinct phases of the 
activation response.  
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Ligand potency controls response rate of CD8+ T cells 
 
To determine how TCR stimulation strength might affect this early response, we selected two 
transcription factors characteristic of the early activation profile, Nr4a1 and Fosb, and examined 
their expression by RNA flow cytometry while modulating TCR signaling strength. We stimulated 
cells with each of four peptides with previously characterized potency for stimulating the OT-I 
TCR5,37: the cognate SIINFEKL peptide (N4); 2 variants with the amino acid changes T4 and G4, 
in decreasing order of potency; and NP68, which does not bind the OT-I TCR. The same 
concentration (1 µM) of each peptide was used, which should saturate MHC occupancy5,11. We 
cultured all cells in equivalent concentrations of exogenous IL-2, as this cytokine is required for T 
cells to enter the cell cycle and proliferate. Given that IL-2 production varies with stimulation 
strength33, addition of exogenous IL-2 enabled us to identify intrinsic changes in gene activation 
that were dependent solely on stimulation strength (Supplementary Fig. 2a,b).  
 
RNA hybridization was verified through examination of the control gene Rpl39 (Supplementary 
Fig. 2c,d). Nr4a1 induction after 1 hour was dependent on ligand strength, with higher potency 
ligands driving a larger percentage of cells expressing Nr4a1 mRNA, in accordance with previous 
studies27,34 (Fig. 2). In cells stimulated with the most potent ligand (N4), this percentage gradually 
declined by 6 hours, but in cells stimulated with the reduced potency ligands (T4 and G4, 
respectively), the percentage of Nr4a1+ cells increased between 3 and 6 hours, suggesting a 
delayed peak in the population response. Cells stimulated with the null peptide NP68 upregulated 
Nr4a1 to a small extent after 1 hour, suggesting a combination of TCR-dependent and -
independent effects on induction. In contrast, Fosb was strongly upregulated at 1 hour and rapidly 
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returned to baseline by 3 hours, regardless of the peptide stimulus. These results indicate that 
within the immediate early burst of transcription factor expression, certain genes exemplified by 
Nr4a1 respond primarily to TCR stimulation, while another set of regulators including Fosb are 
likely driven by TCR-independent factors acting in the first hour of tissue culture. Our observation 
that ligands of lower potency result in reduced immediate and delayed maximum expression of 
Nr4a1 suggests that stimulation strength either alters the rate with which cells embark on a 
universal transcriptional activation pathway or controls the utilization (or coordination) of different 
activation pathways. 
 
To test these possibilities, we performed scRNA-seq on OT-I CD8+ T cells stimulated with the 
same ligands for 6 hours. Protein profiling revealed that reducing ligand potency increased 
heterogeneity in protein markers of early activation (Fig. 3a, Supplementary Fig. 3a). To determine 
whether ligand potency controls transcriptional activation pathways, we combined data from cells 
stimulated for 6 hours with all ligands and the most potent ligand (N4) stimulation time course. 
93% of cells in this combined data set passed quality control filtering, leaving 44-94 cells per 
condition. We excluded cells cultured for only 1 hour to avoid the immediate TCR-independent 
effects described above. Using diffusion pseudotime analysis, we fitted a trajectory to the cells and 
found that it tracked activation status (Fig. 3b). We observed that cells stimulated with medium 
(T4) and low (G4) potency ligands did not follow a different activation trajectory from those 
stimulated with the strongest ligand (N4). This indicated that all ligands promote the same major 
transcriptional changes, including upregulation of biosynthetic and metabolic machinery. As with 
protein expression in the early hours of activation, reducing ligand potency resulted in greater 
heterogeneity with respect to progress along the activation trajectory (Fig. 3c). Cells activated by 
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weaker ligands were not universally less activated, with a proportion of cells achieving activation 
comparable to cells stimulated with the highest potency ligand. This indicates that stimulation 
strength controls the probability of a cell activating at any given moment, regulating the rate with 
which cells initiate transcriptional activation rather than the speed with which they progress once 
activation is initiated. We emphasize that when measurements are summarized across the whole T 
cell population, reduction in activation efficiency would appear as a reduction in the magnitude, 
speed or fraction of cells responding, which have been described in numerous studies (exemplified 
by references13,15,17-21,30). Only through genome-wide single-cell experiments could we distinguish 
the effect of response rate from differences in the percentage, speed of progression, or phenotype 
of responding cells. 
 
Although we found the main activation trajectory to be shared between cells stimulated by high or 
reduced potency ligands, it remained possible that stimulation strength might cause subtle 
deviations. Extensive heterogeneity between cells makes it challenging to directly compare cells 
at the same activation stage after stimulation with different ligands. Even sorting cells based on 
binary measures of activation status8,14,21,28,30,38 might fail to account for heterogeneity within the 
activated populations. A benefit of our single-cell approach is that we can take advantage of the 
heterogeneity within stimulated populations to control for differences in activation state while 
comparing cells stimulated with various ligands. CD69 surface protein expression was strongly 
correlated with transcriptomic activation status, demonstrating activation along our transcriptomic 
trajectory. CD69 expression could therefore be used as an independently measured feature to 
control for activation state in a differential RNA expression analysis between cells treated with the 
various ligands (Supplementary Fig. 3b). This allowed us to ask the question: given the activation 
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state defined by CD69 expression, what is differentially expressed between stimulation 
conditions? Our analysis revealed only a small number of genes expressed at different levels, 
confirming that cells activated by different ligands share a transcriptional response (G4 vs N4, 41 
of 8854 genes, 0.46%; and T4 vs N4, 30 of 8854 genes, 0.34% of genes differentially expressed).  
Expression of a small subset of genes was directly impacted by ligand potency (Fig. 4a, 
Supplementary Tables 2,3). This included downregulated expression of genes encoding 
chemokines such as Xcl1, Ccl3 and Ccl4, particularly in cells stimulated with the low potency (G4) 
ligand, and upregulated expression of genes encoding proteins with roles in class I antigen 
presentation such as Psmb8, Tapbp and B2m, particularly in cells stimulated with the medium 
potency (T4) ligand (Fig. 4b,c, Supplementary Fig. 3c,d). Although many genes, including Ccl3 
and Ccl4 chemokines, have been previously observed to exhibit reduced expression with weak 
ligand stimulation15,28, here we demonstrate that this occurs for only a small subset of genes when 
we account for the activation status of the cells. Of particular importance, genes directing the 
metabolic and biosynthetic programs of T cell activation were not enriched in our differentially 
expressed gene lists, suggesting that all activated cells, regardless of ligand potency, can mount 
these energetic effector differentiation processes. Likewise, early transcription of Gzmb, encoding 
the important cytolytic effector molecule Granzyme B, did not significantly differ between 
stimulation conditions when accounting for cellular activation status (Supplementary Fig. 3e). Our 
results indicate that while there are specific genes involved in leukocyte recruitment and 
endogenous peptide presentation whose expression depends on ligand strength, the overwhelming 
majority of genes expressed in early activation depend on activation status and not the potency of 
the stimulus. 
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Activated T cells achieve the same spectrum of effector phenotypes regardless of stimulation 
potency 
 
Having observed that, regardless of the primary stimulus, activated T cells progress along the same 
transcriptomic activation trajectory, we next examined whether cells exhibited phenotypic 
differences associated with stimulation strength during the first two days of effector T cell 
differentiation. Because OTI T cells can undergo extensive death when activated with soluble 
peptide for multiple days16, we instead used peptide-pulsed APCs to activate naive T cells for two 
days (Supplementary Fig. 4a). In this system, we observed negligible activation after two days by 
the low potency (G4) peptide (Fig. 5a). This is in contrast to pure peptide stimulation with low 
potency ligand, which, consistent with our observations of transcriptional activity at 6 hours, drove 
full activation at two days (Supplementary Fig. 4b). Ex vivo CD8+ OT-I T cells were stimulated 
in IL-2-supplemented media with autologous T-depleted splenocytes (cells remaining after CD8+ 
T cell isolation) pulsed with one of the 4 peptides used in our transcriptomic studies or Q4H7 
peptide, whose potency for stimulating OT-I T cells lies between that of T4 and G4 peptides5 
(medium-low potency). After 2 days of activation, the majority of T cells stimulated with the three 
strongest ligands (N4, T4, Q4H7) were proliferating (Fig. 5a). The proportion of cells in later 
division cycles and the total number of T cells were associated with stimulation strength (Fig. 
5b,c), in agreement with previous observations suggesting an increased percentage of proliferating 
cells, shorter time to first division, or greater proliferation with stronger TCR-pMHC 
interactions11,12,14,16,19,21,27. However, we noted that the most proliferative cells in each condition 
that stimulated proliferation had all undergone 4 divisions, indicating that the few cells that began 
proliferating immediately after stimulation with weaker ligands were not slower to divide. 
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Although it has been previously reported that stimulation strength affects the proportion of 
proliferating cells and the time to first division22, our results now show that weaker ligands do not 
cause a universal delay in proliferation, but rather reduce the number of cells that activate 
immediately. Together with our results from early activation transcriptomic analysis, we conclude 
that ligand potency determines the rate with which an individual cell initiates activation and thus 
the heterogeneity of activation across the population.  
 
Proliferation represents only one component of effector differentiation, and expression of 
cytokines, cytotoxic mediators, and costimulatory or co-inhibitory receptors can control the 
phenotype of differentiated CTLs. In order to examine effector phenotypes without making prior 
assumptions about which proteins would be co-expressed, we used mass cytometry to 
simultaneously measure 19 surface and intracellular proteins related to T cell differentiation and 
effector function. After two days of stimulation with peptide-pulsed autologous T-depleted 
splenocytes, we tested for subpopulations of cells that changed in abundance39 under stimulation 
with any ovalbumin peptide variant compared to the null peptide NP68. The high-dimensional 
space defined by the 19 measured proteins was divided into phenotypic hyperspheres and the 
abundance of cells from each condition was quantified within each hypersphere (Fig. 6a). We 
identified phenotypic hyperspheres that differed significantly in abundance in any peptide 
stimulation condition (Fig. 6b). Examination of protein expression profiles that defined each 
phenotype revealed that, similar to its proliferation profile, the least potent ligand (G4) stimulated 
only a very small proportion of cells to transition from a CD44loCD62Lhi naive phenotype to a 
CD44hiCD62Llo effector phenotype (Fig. 6c, Supplementary Fig. 5). In contrast, stronger ligands 
(N4, T4, and Q4H7) drove increased abundance of effector populations co-expressing many 
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effector-associated proteins including the high affinity IL-2 receptor subunit CD25, the cytotoxic 
mediator Granzyme B, the coinhibitory receptor CTLA-4, and the transcription factor T-bet that 
promotes effector CD8+ T cell differentiation. This effector phenotype was present in all activated 
populations, regardless of the potency of the primary stimulus, and was validated for a subset of 
proteins by flow cytometry (Supplementary Fig. 6a,b). Granzyme B expression levels in Granzyme 
B+ cells were marginally reduced with the highest potency stimulus (N4) (Supplementary Fig. 
6c,d), as observed previously in vivo8, but in contrast to that previous study, we did not observe a 
decrease in the percentage of Granzyme B+ cells with strong stimulation (Supplementary Fig. 6b). 
Of note, IFN-g was not expressed in all effector T cells after two days of stimulation, instead 
emerging in a small subset of cells (up to 20%) primarily under stimulation with ligands of 
medium/medium-low potency (T4 or Q4H7) (Supplementary Fig. 6e-g). Divergence of IFN-γ 
expression from other effector phenotypes was noted in an earlier study14. However, its infrequent 
expression in effector cells and disconnect from other effector protein phenotypes suggests that 
IFN-γ is not representative of cytolytic effector cell differentiation in this system.  
 
We verified effector protein expression phenotypes using wild-type splenocytes as APCs 
(Supplementary Fig. 4c,d). Under wild-type APC activation, G4 stimulation activated a small 
population of cells. These activated cells behaved similarly to those activated by other primary 
stimuli. Together, our phenotypic profiling supports a model in which ligand potency determines 
the rate with which cells embark on effector differentiation but not the spectrum of effector 
phenotypes they can achieve.  
 
All differentiated effector cells are cytolytic 
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The main effector function of CTLs is the targeted release of cytolytic granules upon encountering 
an antigen-presenting target cell. Cytolytic granules carry the lysosome-associated transmembrane 
protein LAMP1, which enables measurement of degranulation in individual cells via the quantity 
of LAMP1 transiently trafficked to the cell surface during antigen challenge. To test how the TCR-
pMHC affinity of a cell’s primary stimulus might affect its degranulation upon subsequent antigen 
encounter, we assayed degranulation of CD8+ T cells activated with ligands of different potencies 
in response to target cell challenge. We first looked at the ability of day-2 CTLs to respond to a 
second stimulus. Co-culture with target cells presenting the cognate N4 peptide drove an increase 
in LAMP1 detected on the cell surface in all effector populations (Fig. 7a). Subsetting cells based 
on division number or CD44 expression revealed that cells in the same activation state exhibited 
similar degranulation profiles upon challenge, regardless of their primary stimulus (Fig. 7b,c). 
Again, use of wild-type APCs for primary stimulation yielded similar results (Supplementary Fig. 
7a-c). After a week in culture, CTLs induced by ligands that drove substantial proliferation and 
effector differentiation (N4, T4, or Q4H7) still demonstrated strong degranulation capacity (Fig. 
7d). Although we observed a slight dependence of degranulation on the potency of the primary 
stimulus (Supplementary Fig. 7d,e), this trend was absent in a target cell killing assay (Fig. 7e). It 
was previously demonstrated that only proliferating cells were competent in cytolytic activity14. 
Our results demonstrate that the converse of this relationship is true by showing that all tested 
ligands that induce proliferation can produce cytolytically competent CTLs.  
 
 
Discussion 
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Previous studies have led to conflicting models of graded and threshold activation responses to 
ligand potency, including T cell response speed, magnitude or proportion of responding 
cells5,11,13,14,17-22,30. We resolve these different interpretations with an unbiased approach revealing 
that ligand potency determines the rate with which cells initiate transcriptional activation. Support 
for our model can be found in studies over the last decade that have looked at specific parts of the 
T cell response: the time to start of proliferation but not proliferation speed was previously found 
to be associated with signal strength22; likewise, low potency Listeria monocytogenes infection 
resulted in curtailed expansion of antigen-specific T cells but complete secondary responses upon 
rechallenge9; and ligand potency was shown to determine the average delay in starting proliferation 
but not CD69 expression in activated cells19,21. We demonstrate that these previous results can all 
be attributed to signal strength-dependent modulation of the rate of response via shared activation 
machinery.  
 
Several in vivo reports have claimed that primary stimulation strength can alter CD8+ T cell 
differentiation fate12,15,23. However, it has been difficult to tease apart the impact of ligand potency 
from that of antigen presentation, costimulatory context, and other cells responding in vivo. The 
duration of T cell-APC interactions influences the magnitude or phenotype of T cell responses in 
different contexts12,36,40,41. In addition, cells stimulated with reduced potency ligands take longer 
on average to accumulate phosphorylated signaling mediators downstream of the TCR19,42 and 
may require more sustained antigen presentation14. Furthermore, the length of time a T cell remains 
conjugated to an APC8,12,43, its motility10,38 and retention time in lymphoid organs in vivo8,9 are 
associated with ligand affinity, and affinity-dependent interaction time is also associated 
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coinhibitory receptor expression43. Therefore, a T cell’s environment will change with ligand 
affinity, which will likely impact in vivo cell fate and not reflect the cell-intrinsic capacity to 
respond. Finally, autocrine and paracrine availability of the cytokine IL-2 modulates T cell 
activation and proliferation11,14,16,24,27,28,44 through PI3K and Myc activity18,26,33,45, and weak 
stimulation can result in insufficient IL-2 to support a proliferative response11,16,27,33,46. However, 
IL-2 secreted by activated CD4+ and CD8+ T cells would likely be expressed in the lymphoid tissue 
microenvironment in a physiological, polyclonal response, and cells stimulated by weak ligands 
can co-opt IL-2 from co-cultured cells stimulated by strong ligands26. Variations between 
experimental protocols pertaining to these factors have left the field unclear as to whether cell-
intrinsic ligand strength-dependent T cell phenotypes exist. We demonstrate that in a controlled 
cellular environment, all activated cells can achieve an effector phenotype via shared 
transcriptional machinery. 
 
Previous in vivo cytotoxicity studies have demonstrated reduced total killing by CTLs induced by 
low potency ligands8,9,12. However, two reports noted that, early after activation, low potency 
stimulation resulted in greater cytolytic capacity per cell compared to high potency stimulation8,9. 
Strongly stimulated T cells were instead retained in the periarteriolar lymphoid sheaths of the 
spleen9 or in the interfollicular regions of the lymph node in a CXCR3-dependent manner8, 
reducing their availability for killing. In our data, RNA expression of Cxcr3 exhibited a non-
significant trend toward downregulation in G4-stimulated cells after accounting for activation 
status at 6 hours (Supplementary Table 2), and genes encoding other chemokines and receptors 
were upregulated with high potency stimulation, suggesting additional potential mechanisms. In 
contrast, in an ex vivo killing assay, CTLs generated in vivo with high or low potency ligands 
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exhibited comparable cytotoxicity28. In our controlled in vitro system, we find that all T cells that 
achieve an effector phenotype are cytolytically competent, suggesting that large divergences 
observed in vivo are not intrinsic to the T cell response to TCR stimulation. 
 
Ligand potency can affect TCR-induced signaling events upstream of transcription including 
calcium fluxes47,48, TCR-coreceptor interaction42, post-translational modifications of signaling 
cascade components5,13,17,19,29,42, and transcription factor nuclear translocation13. Such signaling 
mechanisms may drive the altered rate of transcription initiation that we have identified49. It is 
interesting to consider what might cause specific cells to be the first to respond, particularly to low 
potency stimulation. CD8 and SHP-1 (encoded by Ptpn6) protein expression levels and markers 
of metabolic activity are associated with response propensity in mature CTL50 and naive T cells21, 
respectively. Unfortunately, due to the destructive nature of the single-cell sequencing 
technologies, cells cannot be comprehensively profiled both before and after activation. 
Hypothesis-driven sorting experiments may be fruitful in identifying additional markers of poised 
cells, but ideally a genome-wide screening experiment would be required to understand all 
contributing factors. 
 
Our results emphasize the importance of using single-cell approaches to measure highly 
heterogeneous systems and identify rate-based responses46. These methods have allowed us to 
examine the coordination of mRNA and protein phenotypes in individual cells to answer a 
fundamental question in T cell biology: how does stimulation strength control the cell-intrinsic 
naive T cell response? We demonstrate that the primary effect of ligand affinity is to control the 
rate with which naive T cells initiate activation, not to lower effector gene expression within 
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activated cells or drive the use of alternative transcriptional pathways. Additional environmental 
cues dependent on the nature of the antigen and other responding immune cell populations can 
adjust the ultimate phenotype of each clonal T cell response, but none of these characteristics is 
intrinsically determined by TCR signal strength. Indeed, the fact that heterogeneous, low 
efficiency T cell activation responses can achieve full effector phenotype and function via 
induction of the same genes that mediate synchronous responses to high potency ligands would 
seem fundamental to maintaining flexibility and sensitivity in the immune system. Using response 
rate to modulate clonal population size according to ligand strength makes use of common 
transcriptional machinery while allowing high affinity clones to become the most prevalent and 
suppressing low affinity clones with a near-zero activation rate. This model provides a mechanism 
by which peripheral CD8+ T cells can generate a full CTL response to a vast range of peptide 
antigens with a finite set of rearranged receptors and signaling components.  
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 Methods 
 
Mice  
Mice were bred and housed in the University of Cambridge CBS facility. The genotype of OT-I 
Rag-deficient mice (OT-I Rag1tm1Bal on a C57BL/6 background) was confirmed prior to study. The 
wild-type C57BL/6N mouse line was obtained from the Wellcome Trust Sanger Institute Mouse 
Genetics Project (Sanger MGP). 
 
Cell culture 
The murine lymphoblast EL4 cell line, originally from the Sir William Dunn School of Pathology 
Cell Bank, Oxford, was maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum 
(Biosera) and penicillin-streptomycin (Sigma) and tested negative for mycoplasma. 
Dissected spleens from OT-I Rag1-deficient mice were homogenized through a 70 µm 
filter. CD8+ T cells were isolated using the CD8a+ T Cell Isolation Kit, mouse (Miltenyi).  T cells 
were stimulated either with addition of purified peptide or with pulsed APCs. T-depleted OT-I 
splenocytes (the positive fraction from CD8a+ T cell separation) were used as APCs. Results were 
confirmed using wild-type splenocytes treated with RBC lysis buffer (eBioscience) as APCs. 
APCs were irradiated with ~3000 rad and pulsed for 2 hours with peptide before washing and co-
culture with isolated T cells. OT-I APCs were cultured at a 5:1 ratio and wild-type APCs at a 2.5:1 
ratio with T cells. Where indicated, T cells were stained with proliferation dye eFluor450 
(eBioscience) according to the manufacturer’s instructions before culture. Cells were cultured in 
media composed of complete RPMI 1640 medium (Gibco), 10% fetal bovine serum (Biosera), 
penicillin-streptomycin (Sigma), sodium pyruvate (Gibco), L-glutamine (Sigma), b-
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mercaptoethanol (Gibco), and, unless indicated otherwise, 20 ng/mL (³ 100 U/mL) murine IL-2 
(Peprotech). The following peptides were used for stimulation at 1 µM unless otherwise indicated: 
SIINFEKL (N4), SIITFEKL (T4), SIIQFEHL (Q4H7), SIIGFEKL (G4), and ASNENMDAM 
(NP68) (Cambridge Bioscience). Although 1 µM is a higher concentration than required for 
maximal activation of OT-I cells with pure N4 peptide11,17,33, we sought to keep this variable 
constant across all ligands including G4 for which 1 µM was required to maximize induction of 
CD69 expression19. We observed no inhibitory effect of excess N4 peptide on early activation 
protein phenotypes (Supplementary Fig. 1a).  
 The rate of activation in response to the lowest potency ligand G4 differed between pure 
peptide and peptide-pulsed APC antigen presentation systems. Under pure peptide stimulation, G4 
peptide was capable of activating transcription in approximately half of cells after 6 hours and by 
two days had activated proliferation in the whole population (Fig. 2,3 and Supplementary Fig. 4b). 
In contrast, G4-pulsed APCs induced negligible proliferation at two days (Fig. 5 and 
Supplementary Fig. 4c). These differences may be due to concentration and chronicity of antigen 
presentation, such that changing the antigen presenting system shifts the rate with which each 
ligand activates T cells but does not affect the ordering of these rates or the observation that all 
stimulation conditions capable of driving T cell activation use similar machinery. Our model in 
which ligand potency intrinsically determines relative activation rate is consistent with all of these 
observations. 
 
Sorting for single-cell RNA-seq 
Isolated naive OT-I T cells were stained with proliferation dye. 105 cells per well were stimulated 
with 1 µM peptide in 200 µL media in 96-well round-bottom plates. Cells were washed in PBS, 
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blocked with FcR blocking antibody (clone 93, Biolegend) and stained with Zombie Aqua 
(Biolegend), anti-CD8a eVolve 655 (clone 53-6.7, eBioscience), anti-CD44 APC-eFluor780 or 
APC-FIRE750 (clone IM7, eBioscience or Biolegend, respectively), anti-CD62L PE (clone MEL-
14, eBioscience), anti-CD25 Alexa Fluor 488 (clone PC61.5, eBioscience), and anti-CD69 APC 
(clone H1.2F3, eBioscience). Anti-CD154 PE-Cy7 (clone MR1, Biolegend) and anti-CD71 
PerCP-Cy5.5 (clone R17217, Biolegend) were also included in one experiment, but expression 
levels were largely invariant and therefore not included in the analysis. Cells were sorted on a BD 
Influx (BD Biosciences), selecting live cells that expressed CD8 and that had not proliferated 
(Supplementary Fig. 8a). We did not see proliferation at the time points used for scRNA-seq. 
Expression of all surface proteins was recorded for each indexed cell. Two scRNA-seq 
experiments were performed: experiment 1 consisted of 2 96-well plates of cells stimulated with 
the various peptides for 6 hours; experiment 2 consisted of 4 96-well plates of cells stimulated 
with N4, T4, G4, or NP68 for 6 hours, with N4 for 3 hours, with N4 for 1 hour, or unstimulated. 
Within each experiment, cells from all conditions were included on each plate to avoid 
confounding of technical effects between plates. In each experiment, at least one well was left 
blank (without a cell) to monitor background levels of ambient RNA. 
 
Single-cell RNA-seq 
Sequencing library preparation was adapted from Picelli et al51 with the following modifications. 
Cells were sorted into 96-well plates holding 4 µL of lysis buffer composed of 2.3 U SUPERase 
In RNase inhibitor (Thermo Fisher Scientific), 0.11 % (v/v) Triton X-100 (Sigma), 12.5 mM DTT 
(Thermo Fisher Scientific), and 2.5 mM dNTP mix (Thermo Fisher Scientific). 1 µL annealing 
mix containing ERCC RNA Spike-In Mix (Thermo Fisher Scientific; final dilution 1 in 3 x 107) 
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and 10 µM oligo-dT30VN (Sigma) was added to each well before reverse transcription with 
SuperScript II (Invitrogen). cDNA amplification was performed with 23 PCR cycles and the 
resulting PCR products purified with Ampure XP Beads (Agencourt) at a volume ratio of 0.7:1 
beads:DNA. Libraries were prepared using the Nextera XT DNA Sample Preparation Kit and 
indexes from the Nextera XT Index Kit v2 Set A and Nextera XT Index Kit v2 Set D (Illumina).  
Each plate of libraries was pooled, cleaned with Ampure XP beads, and quantified using KAPA 
Library Quantification Kit (Roche). Equimolar quantities of libraries from each plate were 
combined for sequencing. Single-end 50bp sequencing was performed using a HiSeq 4000 
(Illumina). Experiment 1 was sequenced in a single lane. Experiment 2 was sequenced on two 
lanes and the data merged.  
 
Single-cell RNA-seq alignment and QC 
Sequencing reads were aligned to the mm10 genome and ERCC transcripts using subread v 1.5.152 
in RNA-seq mode with unique mapping. The number of reads mapping to exonic regions of each 
gene were counted using featureCounts53 (implemented in Rsubread v1.20.6) with a minimum 
quality score threshold of 10 and annotation from Ensembl GRCm38 version 82. Each sequencing 
run was aligned and counted separately. For cells sequenced twice, counts were summed.  
Data were organized using the scran and scater Bioconductor packages54,55. Cells were 
filtered as follows for quality control: exclusion of samples where FACS had recorded multiple 
sorted cells; exclusion of cells with low numbers of mapped reads or genes detected (threshold 
defined as 3 MADs below the median log10-value); exclusion of cells with a high percentage of 
reads mapped to ERCC spike-in controls or mitochondrial genes (3 MADs above the median 
value); exclusion of cells with high or low ratio of ERCC spike-in controls to endogenous genes 
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(3 MADs from the median difference of log2-values). All filters were applied on the whole data 
set and the union of excluded cells were removed. After filtering, experiment 1 retained 184 of 
191 sorted cells, and experiment 2 retained 344 of 376 sorted cells. Blank wells were automatically 
excluded through the filtering steps.  
 
Single-cell RNA-seq analysis 
Within each sequencing run, genes were filtered for those detected in at least 5% of cells and those 
with a mean count of at least 1. Data was normalized using size factors calculated from ERCC 
spike-in controls to account for variation in total mRNA56. Log2-transformation was performed on 
the normalized expression values, after adding a pseudocount of 1. Batch effects between 96-well 
plates were removed by applying ComBat57 in the sva Bioconductor package to the log-expression 
values, including stimulation condition as a preserved covariate. For analyses of the combined 
data, genes were required to meet filtering criteria in both sequencing data sets before following 
the same normalization and batch correction procedure on the combined data.   
Non-branching diffusion pseudotime analysis was performed using a modified version of 
the dpt package31 to create a diffusion map of the cells and find the most probable activation 
trajectory. Analysis was performed using the first 50 scaled principal components and a Euclidean 
distance metric. The starting point of the fit trajectory, at pseudotime 0, is known as the root cell. 
We required that the root cell be from the unstimulated condition.  In the situation in which a root 
cell was not automatically identified from this condition, pseudotime was fit to only the subset of 
cells from the most and least stimulated conditions to find a root cell, and this cell was subsequently 
used as root in the full analysis. Clustering along pseudotime was performed using the classInt 
package for 1-dimensional class interval selection using the “jenks” method. To identify the most 
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biologically variable genes among unstimulated cells, we first used the trendVar function of the 
scran Bioconductor package54 to fit a parametric curve followed by loess smoothing (span = 0.95) 
to the variance versus the mean log-expression of the spike-in transcripts. Biological variances of 
endogenous genes were then obtained by decomposing the variance using the decomposeVar 
function. Heatmaps were generated using the pheatmap R package. 
Differential expression analyses were performed by GLM in edgeR58,59 with a likelihood 
ratio test, using effective library sizes derived from the spike-in size factors and blocking on the 
plate of origin for each cell. We performed differential expression analysis between stimuli of 
varying affinities while controlling for activation status by additionally blocking on a spline basis 
matrix (4 degrees of freedom) for log10 CD69 protein expression within each sequencing run to 
allow for non-linear trends in protein expression. 
GO category enrichment of differentially expressed genes (FDR < 0.05) was performed 
using the goana function from the limma Bioconductor package. The significance threshold for 
enrichment was set at FDR < 0.05 (Benjamini Hochberg procedure). Transcriptional regulatory 
gene enrichment was calculated by hypergeometric test of enrichment for transcription factor 
genes (annotated in TcoF-DB v260) within genes significantly upregulated (log-FC > 0, FDR < 
0.05) in the early activation cluster compared with resting and late activation clusters. The gene 
universe for this analysis consisted of all genes tested for differential expression. 
 
RNA flow cytometry 
Control genes for RNA flow cytometry were determined from scRNA-seq data. We began with 
the sequencing run containing both the high potency ligand (N4) time course and reduced potency 
ligand stimulations for 6 hours (experiment 2). Genes were filtered for those detected in at least 
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80% of cells in each condition. Gene variances were calculated from the spike-in-normalized, log-
transformed reads for each plate separately and averaged. We then performed an ANOVA test on 
the expression of each gene with respect to condition using the full spike-in-normalized, log-
transformed, batch-corrected data set. Genes were filtered based on an average variance less than 
2 and an ANOVA p value greater than 0.01. The top non-pseudogenes in this list were Slc34a2 
and Rpl39. Examining these genes in scRNAseq experiment 1 (consisting of only 6-hour 
stimulated samples) revealed that Slc34a2 maintained a lack of bias by stimulation condition, and 
Rpl39 expression was slighlty different between conditions, significant by ANOVA without 
multiple testing correction. Both genes remained strongly expressed across cells. A PrimeFlow 
expression assay (Thermo Fisher Scientific) with detectable signal was not available for Slc34a2, 
so Rpl39 was used as a control gene to check that cells were permeabilized and probes hybridized 
and amplified. 
Isolated naive OT-I T cells were stimulated with 1 µM peptide for 0-6 hours in complete 
media as in the scRNA-seq experiment. After stimulation, cells were immediately moved to ice 
before RNA flow cytometry was performed using the PrimeFlow system (Thermo Fisher 
Scientific). Cell surfaces were stained with Zombie Aqua Fixable Viability Kit (Biolegend) before 
fixation and permeabilization. Cells were stained with Nr4a1 AF568, Fosb AF647, and Rpl39 
AF488. Data were acquired on a BD LSRFortessa and analyzed in FlowJo (Supplementary Fig. 
8b). 
 
Mass cytometry 
Cells from two mice were stimulated separately with irradiated autologous T-depleted splenocytes 
pulsed with 1 µM N4, T4, Q4H7, G4 or NP68 peptide. For each condition, two million isolated 
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naive OT-I T cells were mixed with 10 million peptide-pulsed APCs in 4 mL media in 6-well 
plates. Antibodies for mass cytometry are listed in Supplementary Table 4. 155Gd-anti-CD44 
(clone IM7) and 160Gd-anti-PE (clone PE001) were conjugated from Biolegend MaxPar Ready 
antibodies using the Maxpar Antibody Labeling Kit (Fluidigm) according to the manufacturer’s 
instructions with 83 and 74 µg antibody, respectively. All antibodies were directly conjugated to 
metals except for CD62L-APC, CD11a-FITC, and LAMP1-PE, which were then probed with 
metal-conjugated anti-APC, anti-FITC, and anti-PE antibodies, respectively. Staining for mass 
cytometry was performed using sequential MaxPar reagent kits (Fluidigm) in the following steps. 
Live cells were stained with 0.25 µM Cell ID Cisplatin for 5 minutes at room temperature. Three 
million cells from each sample were barcoded using the Cell-ID 20-Plex Pd Barcoding Kit and 
pooled for staining. For surface staining, cells were blocked with 1 µg FcR blocking antibody 
(clone 93, Biolegend) per million cells before staining with primary followed by secondary 
antibodies, all in MaxPar Cell Staining Buffer. For intracellular staining, cells were fixed and 
permeabilized with the Maxpar Nuclear Antigen Staining Buffer Set. Cells were again incubated 
with FcR blocking reagent before staining with primary and secondary intracellular antibodies, all 
in Nuclear Antigen Staining Perm. After washing with Nuclear Antigen Staining Perm and Cell 
Staining Buffer, cells were stained overnight in 125 nM Cell-ID Intercalator-Ir in Maxpar Fix and 
Perm Buffer before analyzing on a Helios CyTOF system (Fluidigm) using Fluidigm CyTOF 
Software to collect and process the data. We note that intracellular IFN-g measurements were made 
without addition of a Golgi-interrupting compound to avoid effects on other intracellular 
components measured. 
 
Mass cytometry data analysis 
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Mass cytometry data was analyzed using the cydar Bioconductor package39. Cells were pooled 
across samples and mass-labelled marker values were transformed using the Logicle 
transformation61. We imposed the following filters sequentially: removal of cells acquired during 
a clog in the Helios machine, removal of normalization beads, inclusion of singlet cells labelled 
with Ir191 and Ir193 DNA markers, removal of dead cells labelled with high levels of Pt195, 
removal of cells expressing extremely low levels of the hematopoietic marker CD45 (5 MAD 
filter), removal of non-T cells marked by extremely low expression of TCRb and CD8a (6 MAD 
and 5 MAD filters, respectively, because surface TCRb and CD8a expression can drop 
dramatically with internalization upon activation). Cells were assigned to hyperspheres with a 
radius defined from a per-marker log-intensity tolerance of 0.5, and differential abundance was 
analyzed using the edgeR Bioconductor package with a quasi-likelihood GLM fit62 including the 
mouse of origin as a blocking factor for each sample.  Significant hyperspheres were identified by 
analysis of deviance to detect those with differential abundance in any condition, controlling the 
spatial FDR at 5%. A t-SNE plot was generated using the Rtsne package63 with a perplexity value 
of 50. 
 
Flow cytometry 
FC receptors were blocked with anti-mouse CD16/32 (clone 93, Biolegend) before staining. Dead 
cells were identified using the Zombie Aqua Fixable Viability Kit (Biolegend). Cells were stained 
with the following antibody clones: anti-mouse CD8a (clone 53-6.7, Biolegend), anti-
mouse/human CD44 (clone IM7, Biolegend), anti-mouse CD62L (clone MEL-14, eBioscience), 
anti-mouse/human Granzyme B (clone GB11, Biolegend), anti-mouse CTLA4 (clone UC1-4B9, 
Biolegend), anti-mouse CD25 (clone PC61.5, eBioscience), and anti-mouse IFN-g (clone 
 31 
XMG1.2, Biolegend). Intracellular staining of Granzyme B, CTLA-4, and IFN-g was performed 
using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). To count cells, 123count 
eBeads (eBioscience) were added to flow cytometry tubes immediately before flow cytometer 
acquisition. Data was acquired on a BD LSRFortessa and analyzed in FlowJo. Cells were gated 
for size, single cells, living cells, and CD8+ cells before examination of proliferation curves 
(Supplementary Fig. 8c). Cells were further gated on proliferation dye+ cells to exclude any CD8+ 
T cells in the APC fraction before quantification of division numbers and examination of surface 
and intracellular proteins. Statistical analyses of results from separate mice were performed using 
GraphPad Prism software. 
 
Degranulation assay 
Activated T cells were assayed for degranulation upon challenge with ovalbumin (N4)-pulsed EL4 
cells or antibody-based TCR stimulation. Cells were stained with proliferation dye eFluor 450 
(eBioscience) before stimulation to measure this parameter in degranulating cells. For cellular 
challenge, EL4 cells were pulsed with 1 µM of the highest potency N4 peptide for 1 hour and 
washed. Un-pulsed EL4 cells were used as a control. T cell stimulation cultures were mixed 1:1 
with EL4 cells in media supplemented with anti-mouse LAMP1 PE (clone eBio1D4B, 
eBioscience, 2 µg/mL). For antibody-based challenge, CTLs were cultured on plates coated with 
1 µM anti-CD3e (clone 145-2C11, BD Biosciences) for 1 hour at 37 °C. After 3 hours, cells were 
stained on ice. FC receptors were blocked with anti-mouse CD16/32 (clone 93, Biolegend) and 
cells were stained with the Zombie Aqua Fixable Viability Kit (Biolegend) and antibodies to CD8a 
(53-6.7, Biolegend) and CD44 (IM7, Biolegend). Data were acquired immediately on a BD 
LSRFortessa and analyzed in FlowJo. Cells were gated for size, single cells, living cells, and CD8+ 
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cells before examination of LAMP1 surface trafficking (Supplementary Fig. 8d,e). For samples 
activated for 2 days before degranulation testing, cells were also gated on proliferation dye+ cells 
to exclude any T cells in the residual irradiated APC population where necessary. Where possible, 
samples were run in duplicate and measurements averaged. Statistical analyses of results from 
separate mice were performed using GraphPad Prism software. 
 
Killing assay 
After 8 days of activation, activated T cells were assayed for their ability to kill ovalbumin (N4)-
pulsed EL4 cells. Cells were plated at T:EL4 cell ratios ranging from 10:1 to 0.3125:1 in round-
bottom 96-well plates in RPMI without phenol red (Gibco), supplemented with 2% fetal bovine 
serum. EL4 cells without ovalbumin pulse were used as a control. Maximum death was estimated 
by adding lysis buffer to the same number of EL4 cells. All conditions were performed in duplicate. 
Cells were co-cultured for 3 hours and EL4 cell death assessed by lactate dehydrogenase (LDH) 
release using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). Absorbances at 
490nm were read on a VersaMax microplate reader (Molecular Devices) using SoftmaxPro 5.4.1 
software. Changes in absorbance between wells containing pulsed and un-pulsed EL4 wells were 
calculated and compared to maximum EL4 death. Statistical analyses of results from separate mice 
were performed using GraphPad Prism software. 
 
Ethics statement 
This research has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and 
Ethical Review Body (AWERB).  
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Mass cytometry data are available in the Cytobank repository, accession number 66456. The 
remaining data that support the findings of this study are available from the corresponding authors 
upon request. 
 
Code availability statement 
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https://github.com/MarioniLab/SingleCellAPL2018. 
 
Reporting summary 
Additional information can be found in the Life Sciences Reporting Summary included with this 
article. 
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Figure Legends 
 
Fig. 1: A burst of transcriptional regulatory machinery characterizes early T cell activation. 
a, OT-I CD8+ T cells were stimulated with high potency ovalbumin peptide (N4) for 0, 1, 3, or 6 
hours before sorting for scRNA-seq by FACS. Protein expression flow cytometry measurements 
are representative of at least 2 independent experiments, except CD44 expression at 1h and 3h 
measured only in this experiment. b, Principal components analysis of scRNA-seq of cells sorted 
in a. c, Diffusion pseudotime analysis of sequenced cells: cells are plotted by diffusion components 
(DCs) 1 and 2, with a black line delineating the pseudotime trajectory. d, Plot in c is colored by 
clusters in diffusion pseudotime. e, The top 20 genes transcriptionally upregulated in the early 
activation cluster versus the resting and late activation clusters are depicted in a heatmap with 
genes clustered by Pearson correlation. Blue (TR) indicates transcriptional regulatory genes. f, 
Expression of selected transcription factors from e is shown with a box plot indicating the median, 
boxed interquartile range, and whiskers extending to the most extreme point up to 1.5 x the 
interquartile range. (b-f) n = 44 cells for 0h, 51 for 1h, 64 for 3h, and 46 for 6h. 
 
Fig. 2: Early response genes can be TCR-dependent or TCR-independent. a, OT-I CD8+ T 
cells were stimulated with high potency N4 peptide, reduced potency ligands (T4 or G4) or a non-
binding control peptide (NP68) for the indicated times before examination of Nr4a1 and Fosb 
expression by RNA flow cytometry. Samples were gated on live cells in which the control gene 
Rpl39 was detected. b, Plots depict the percentage of cells detected expressing each transcription 
factor. Results (a, b) are representative of 3 independent experiments. 
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Fig. 3: Ligand potency determines activation rate. OT-I CD8+ T cells were stimulated for 6 
hours with the various peptide ligands or for 3 hours with high affinity (N4) peptide for scRNA-
seq. a, Violin plots depict the distribution of surface protein expression measurements in 
sequenced cells stimulated for 6 hours; n = 45 cells for N4, 44 for T4, 48 for G4, and 47 for NP68. 
A second independent experiment is depicted in Supplementary Fig. 3a. b, An activation trajectory 
was fit to the transcriptomic data by diffusion pseudotime analysis; n = 91 cells for N4 6h, 91 for 
T4 6h,  94 for G4 6h, 93 for NP68 6h, 64 for N4 3h, and 44 for unstimulated. Plot depicts combined 
data from two independent scRNA-seq experiments. c, Distribution of cells along the pseudotime 
transcriptomic activation trajectory fit in b separated by stimulation condition.  
 
Fig. 4: Differential expression between cells activated by ligands of different potencies 
accounting for activation status. a, Log2-fold changes from a differential expression analysis 
between T4 (medium potency) and N4 (high potency), or G4 (low potency) and N4, peptide stimuli 
in Fig. 3, accounting for each cell’s activation status as defined by log10 CD69 surface protein 
expression. Plot depicts all 8854 genes tested; differentially expressed genes (FDR < 0.05) for T4 
versus N4 are shown in green; G4 versus N4, blue; intersection of T4 versus N4 and G4 versus 
N4, magenta and labelled. b, Residual expression of selected chemokine genes in scRNA-seq data 
after accounting for CD69 surface protein expression, plotted by stimulation condition. c, As b for 
selected genes associated with class I antigen presentation. (b-c) Box plots show the median, boxed 
interquartile range, and whiskers extending to the most extreme point up to 1.5 x the interquartile 
range; n = 155 cells for N4, 91 for T4, 94 for G4. * FDR < 0.05; statistical test described in Methods 
and statistics detailed in Supplementary Table 2.  
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Fig. 5: Cell number but not maximal division number is associated with ligand potency. a, 
OT-I CD8+ T cells were stimulated with autologous T-depleted splenocytes pulsed with various 
peptides. After 2 days, proliferation was measured by flow cytometry. Results are representative 
of 10 separate mice in 7 independent experiments. b, Cells activated as in a were counted and 
normalized to the null peptide (NP68) condition. Plot depicts counts from 6 separate mice in 5 
independent experiments; line indicates mean and error bars denote SEM. c, Mean percentages of 
cells in each division cycle were quantified from the 10 separate mice in 7 independent 
experiments described in a; error bars depict SEM. 
 
Fig. 6: Effector T cells exhibit the spectrum of phenotypes, regardless of primary stimulation 
strength. a, A schematic of differential abundance testing for mass cytometry data using cydar 
software demonstrates how cells are assigned to hyperspheres and how the abundance of cells 
within each hypersphere is compared between conditions. b, OT-I CD8+ T cells from two separate 
mice were stimulated as in Fig. 5 for 2 days before profiling activation markers by mass cytometry. 
Analysis identified subpopulations of cells that changed in abundance with any stimulus. Plots 
depict a t-SNE visualization of the significantly differentially abundant hyperspheres (FDR < 0.05, 
5138 of 5160 tested), colored by their log2 fold-change in abundance between NP68 (null peptide) 
stimulation and the indicated ovalbumin peptide variant (statistical test described in Methods). c, 
The plot from b is colored by marker intensity for selected proteins. 
 
Fig. 7: All activated CD8+ T cells can degranulate regardless of the affinity of their primary 
stimulus. a, OTI CD8+ T cells activated for 2 days as in Fig. 5 and 6 were challenged with high 
potency ovalbumin peptide (N4)-pulsed EL4 cells for 3 hours. Degranulation was quantified by 
 38 
adding anti-LAMP1 PE to the cell culture medium to measure lysosomal trafficking by flow 
cytometry. b, Cells in a were gated based on their proliferation dye intensity to identify those that 
had divided 0, 1, 2, 3, or 4 times before comparing LAMP1 median fluorescence intensity (MFI). 
c, As in b, CD44hi cells were gated before comparing LAMP1 MFI. Bar plots (b-c) depict mean 
of two technical replicates in one representative experiment. Results (a-b) are representative of 6 
separate mice from 5 independent experiments and (c) 5 separate mice from 4 independent 
experiments. d, T cells stimulated as in a were cultured for 7 days before a 3-hour challenge with 
ovalbumin peptide (N4)-pulsed EL4 cells (left) or plate-bound anti-CD3e (right). Results are 
representative of 8 and 5 separate mice examined in 6 and 4 independent experiments, respectively. 
e, T cells activated as in a were cultured until day 8 and were tested for their ability to kill N4-
pulsed EL4 cells by LDH release assay. Plot depicts combined data from 5 separate mice in 3 
independent experiments; mean plotted with error bars representing SEM. 
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